Temporal Concept – Page 27

Biopharma Layoff Tracker 2024: Anokion, GlycoMimetics, Relay and More Cut Staff

1 year ago talkbio0Tagged 2024, Anokion, Biopharma, GlycoMimetics, Industry, layoffs, Relay Device, restructuring, trends qualifier

Biopharma, Layoffs, 2024, Anokion, GlycoMimetics, Relay, Restructuring, Job Cuts, Industry Trends

SEC Staff Recommends Enforcement Action Against Allarity Over Potential Federal Securities Laws Violations

1 year ago talkbio0Tagged Allarity, Clinical action, Dovitinib, enforcement, federal, Rules of conduct, seconds, stenoparib, United States Food and Drug Administration, Violations

Allarity Therapeutics, SEC, Enforcement Action, Federal Securities Laws, Violations, Wells Notice, FDA, Dovitinib, Stenoparib

Lexeo Therapeutics Reports Promising Early Data for Gene Therapy LX2006 in Friedreich Ataxia Cardiomyopathy

1 year ago talkbio0Tagged Ataxia, Cardiomyopathies, Clinical Trials, gene therapy, Hereditary Diseases, Infrequent, Lexeo, LX2006

Lexeo Therapeutics, LX2006, Gene Therapy, Friedreich Ataxia, Cardiomyopathy, Clinical Trials, Rare Genetic Disorders

FDA Rejects Novo Nordisk’s Once-Weekly Insulin Icodec for Diabetes Treatment

1 year ago talkbio0Tagged Complete, Diabetes, Diabetes Mellitus, Non-Insulin-Dependent, Icodec, Insulin, Nordisk, Response process, United States Food and Drug Administration, Weekly

FDA, Novo Nordisk, Icodec, Weekly Insulin, Diabetes Treatment, Type 1 Diabetes, Type 2 Diabetes, Complete Response Letter

Flagship’s Noubar Afeyan on Uncertainty, AI, and the Future of Biotechnology

1 year ago talkbio0Tagged Artificial Intelligence, Artificial Intelligence, biotech, Capital, Flagship, Future, innovation, Moderna, Noubar Afeyan, Pioneering, venture

, Noubar Afeyan, Flagship Pioneering, Biotechnology, Artificial Intelligence (AI), Uncertainty, Innovation, Future of Biotech, Moderna, Venture Capital,

Compensation Trends in the Pharmaceutical and Biotech Industry: 2023 Insights

1 year ago talkbio0Tagged Drug Industry, Midline (qualifier value), trends qualifier, Wages

pharmaceutical industry, biotech companies, median salary, employee pay, compensation trends, 2023

UniQure Wins First FDA RMAT in Huntington’s Disease After Strong Phase I/II Data

1 year ago talkbio0Tagged AMT-130, Clinical Trials, Composite, cUHDRS, Disease Progression, gene therapy, Huntington 's disease, Huntington 's Disease Rating Scale, Identifier, NEFL gene, Neurodegenerative Disorders, NfL, Phase, RMAT, Unified - Type of Agreement, UniQure, United States Food and Drug Administration

UniQure, Huntington’s disease, gene therapy, AMT-130, FDA, RMAT designation, Phase I/II clinical trials, neurodegenerative disorder, neurofilament light (NfL), disease progression, composite Unified Huntington’s Disease Rating Scale (cUHDRS).